Presently, 260 drug candidates are being evaluated in clinical / preclinical stages for the treatment >>

The concept of microbiome-based therapeutics has generated significant enthusiasm within the medical science community, defining a new frontier in the field of medicine. Despite having captured the interest of several venture capital firms and big pharma players, no microbiome-based therapeutic has been officially approved by an authorized medical product regulator. However, the current development pipeline of microbiome therapeutics has several promising candidates that are likely to result in commercial success stories soon.
To order this 640+ page report, which features 235+ figures and 275+ tables, please visit this link
The USD 4 billion (by 2030) financial opportunity within the microbiome therapeutics (Tx) market and diagnostics (Dx) markets, has been analyzed across the following segments:
Type of Therapy (Tx)
Prescription Drug
Type of Molecule (Tx)
Small Molecules
Target Indication (Tx+Dx)
Acne Vulgaris
Atopic Dermatitis
Clostridium difficile Infection
Colorectal Cancer
Crohn’s Disease
Irritable Bowel Syndrome
Lactose Intolerance
Lung Cancer
Nonalcoholic steatohepatitis (NASH)
Ulcerative colitis
Therapeutic Area (Tx+Dx)
Autoimmune Disorders
Dental Disorders
Digestive and Gastrointestinal Disorders
Dermatological Disorders
Infectious Disease
Metabolic Disorders
Key Geographical Regions (Tx+Dx)
North America
Asia-Pacific and Rest of the World
The Human Microbiome Market, 2019-2030 report features the following companies, which we identified to be key players in this domain: 
  • 4D Pharma
  • Armata Pharmaceuticals
  • Evelo Biosciences
  • Rebiotix (Acquired by Ferring Pharmaceuticals)
  • Seres Therapeutics
  • Vedanta Biosciences
Table of Contents
Executive Summary
Microbiome Therapeutics: Market Landscape
Company and Drug Profiles
Microbiome Diagnostics: Market Landscape
Fecal Microbiota Therapy (FMT)
Attractiveness Competitiveness (AC) Matrix
Microbiome Related Initiatives of Big Pharmaceutical Players
Start-up Health Indexing
Key Therapeutics Areas
Funding and Investment Analysis
Contract Services for Microbiome Therapeutics
Big Data and Microbiome Therapeutics
Microbiome Therapeutics: Market Forecast and Opportunity Analysis
Microbiome Diagnostics: Market Forecast and Opportunity Analysis
Fecal Microbiota Therapies: Market Forecast and Opportunity Analysis
Case Study: Microbiome-based Products in Other Industries
Concluding Remarks
Executive Insights
Appendix I: Tabulated Data
Appendix II: List of Companies and Organizations
To purchase a copy, please visit
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
[email protected]

You may also like


No comments yet... Be the first to leave a reply! Login here

0 Karma
732 Posts

Made with by Mamby